| Management of childhood onset nephrotic syndrome. | |
MedLine Citation:
|
PMID: 19651590 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The therapeutic approach to childhood nephrotic syndrome is based on a series of studies that began with an international collaborative effort sponsored by the International Study of Kidney Disease in Children in 1967. The characteristics of children presenting with nephrotic syndrome have changed over recent decades with greater frequency of the challenging condition focal segmental glomerulosclerosis and a greater prevalence of obesity and diabetes mellitus, which may be resistant to glucocorticoids in the former and exacerbated by long-term glucocorticoid therapy in the latter 2 conditions. The Children's Nephrotic Syndrome Consensus Conference was formed to systematically review the published literature and generate a children's primary nephrotic syndrome guideline for use in educational, therapeutic, and research venues. |
Authors:
|
Debbie S Gipson; Susan F Massengill; Lynne Yao; Shashi Nagaraj; William E Smoyer; John D Mahan; Delbert Wigfall; Paul Miles; Leslie Powell; Jen-Jar Lin; Howard Trachtman; Larry A Greenbaum |
Publication Detail:
|
Type: Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. Date: 2009-07-27 |
Journal Detail:
|
Title: Pediatrics Volume: 124 ISSN: 1098-4275 ISO Abbreviation: Pediatrics Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-08-04 Completed Date: 2009-08-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0376422 Medline TA: Pediatrics Country: United States |
Other Details:
|
Languages: eng Pagination: 747-57 Citation Subset: AIM; IM |
Affiliation:
|
Division of Nephrology and Hypertension, Department ofMedicine and Pediatrics, University of North Carolina, ChapelHill, North Carolina 27599-7155, USA. debbie_gipson@med.unc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects,
therapeutic use Biopsy Child Combined Modality Therapy Cyclophosphamide / adverse effects, therapeutic use Cyclosporine / adverse effects, therapeutic use Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance Drug Therapy, Combination Glucocorticoids / adverse effects, therapeutic use* Humans Immunosuppressive Agents / adverse effects, therapeutic use Kidney / pathology Kidney Function Tests Mycophenolic Acid / adverse effects, analogs & derivatives, therapeutic use Nephrosis, Lipoid / classification, diagnosis, drug therapy, pathology Nephrotic Syndrome / classification, diagnosis, drug therapy*, pathology Prednisone / adverse effects, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
2 U18HS10397-08/HS/AHRQ HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Glucocorticoids; 0/Immunosuppressive Agents; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 59865-13-3/Cyclosporine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Do school-based asthma education programs improve self-management and health outcomes?
Next Document: Pedestrian safety.